Biogen's 2022 outlook leaves investors wanting, shares slip
Biogen expects "minimal" revenue this year from its Alzheimers treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping...
Biogen expects "minimal" revenue this year from its Alzheimers treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping...